Claims
- 1. A composition for treating renal fibrosis, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carriers, said compound being a member of a group having the general formula:
- 2. The composition of claim 1, wherein said compound is halofuginone.
- 3. The composition of claim 1 wherein said pharmaceutically acceptable carrier enables administration of the composition orally or parenterally in form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.
- 4. A method for treating renal fibrosis in a subject, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a compound having the general formula:
- 5. The method of claim 4, wherein said compound is halofuginone.
- 6. The method of claim 4, wherein said pharmaceutical composition is suitable for administration orally or parenterally in the form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.
- 7. The method of claim 4, wherein the renal fibrosis condition is primary or secondary.
- 8. The method of claim 7 wherein the secondary condition is caused by hypertension, diabetic complications, or autoimmune diseases.
- 9. A method for preventing renal fibrosis from progressing to end-stage renal failure comprising administering to a subject in need thereof a therapeutically effective amount of compound in a pharmaceutically acceptable carrier, said compound being a member of a group having the general formula:
- 10. The method of claim 9, wherein said compound is halofuginone.
- 11. The method of claim 9, wherein said pharmaceutically acceptable carrier enables administration of the composition orally or parenterally in the form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.
- 12. A method for preparing a pharmaceutical composition for treating renal fibrosis which comprises combining a compound being a member of the group having the general formula:
- 13. The method of claim 12, wherein the compound is halofuginone.
- 14. The method of claim 12, wherein said medicament is suitable for administration orally or parenterally in the form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.
Priority Claims (1)
Number |
Date |
Country |
Kind |
IL143366 |
May 2001 |
IL |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of International application PCT/IL02/00408 filed May 23, 2002, the entire content of which is expressly incorporated herein by reference thereto.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/IL02/00408 |
May 2002 |
US |
Child |
10723918 |
Nov 2003 |
US |